Table 6 EORTC QLQ-CR38 scores with respect to tumor location, gender and symptoms of urgency and fecal soiling
EORTC QLQ-CR38 components | Total | Tumor location in rectum | Gender | Urgency | Fecal soiling | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prox. | Mid. | Distal |  | F | M |  | (+) | (−) |  | (+) | (−) |  | ||
Functional scales | Median (min-max) | Median (min-max) | Pa | Median (min-max) | Pa | Median (min-max) | Pa | Median (min-max) | P a | |||||
 Body image (n = 26) | 77.8 (33.3–100) | 88.9 (55.6–100) | 66.7 (33.3–100) | 94.4 (33.3–100) | NA | 88.9 (33.3–100) | 61.1 (33.3–100) | 0.274 | 66.7 (33.3–100) | 100 (33.3–100) | 0.151 | 66.7 (33.3–100) | 77.8 (33.3–100) | 0.469 |
 Future perspective (n = 25) | 66.7 (0–100) | 83.3 (66.7–100) | 66.7 (0–100) | 66.7 (0–100) | NA | 66.7 (0–100) | 66.7 (0–100) | 0.727 | 66.7 (0–100) | 100 (66.7–100) | 0.010 | 66.7 (33.3–100) | 66.7 (0–100) | 0.855 |
 Sexual functioning (n = 29) | 33.3 (0–66.7) | 8.3 (0–33.3) | 33.3 (0–66.7) | 33.3 (0–66.7) | NA | 0 (0–66.7) | 33.3 (0–66.7) | 0.172 | 0 (0–66.7) | 33.3 (16.7–66.7) | 0.016 | 16.7 (0–50) | 33.3 (0–66.7) | 0.521 |
 Sexual enjoyment (n = 24) | 0 (0–66.7) | 0 (0–33.3) | 0 (0–33.3) | 0 (0–66.7) | NA | 0 (0–33.3) | 0 (0–66.7) | 0.977 | 0 (0–33.3) | 0 (0–66.7) | 0.634 | 0 (0–0) | 0 (0–66.7) | 0.273 |
Symptom scales | ||||||||||||||
 Rad-induced micturition (n = 29) | 22.2 (0–77.8) | 16.7 (0–44.4) | 22.2 (0–55.6) | 27.8 (0–77.8) | NA | 11.1 (0–77.8) | 33.3 (0–66.7) | 0.112 | 22.2 (0.7–7.8) | 5.6 (0–66.7) | 0.206 | 22.2 (11.1–66.7) | 11.1 (0–77.8) | 0.250 |
 Chemotherapy side effects (n = 29) | 11.1 (0–100) | 27.8 (0–100) | 11.1 (0–33.3) | 11.1 (0–33.3) | NA | 11.1 (0–100) | 11.1 (0–33.3) | 0.477 | 11.1 (0–100) | 0 (0–22.2) | 0.023 | 11.1 (0–22.2) | 11.1 (0–100) | 0.304 |
 Gastrointesti-nal symptoms (n = 29) | 20 (0–60) | 30 (0–60) | 6.7 (0–53.3) | 20 (0–53.3) | NA | 20 (0–60) | 13.3 (0–53.3) | 0.425 | 20 (0–60) | 6.7 (0–26.7) | 0.114 | 20 (0–53.3) | 16.7 (0–60) | 0.685 |
 Sexual dysfunction of men (n = 11) | 50 (0–100) | 0 (0–0) | 100 (33.3–100) | 41.7 (16.7–100) | NA | – | 50 (0–100) | NA | 58.3 (16.7–100) | 16.7 (0–100) | 0.294 | 33.3 (0–100) | 75 (16.7–100) | 0.496 |
 Sexual dysfunction of women (n = 4) | 0 (0–50) | 50 (50–50) | – | 0 (0–0) | NA | 50 (0–100) | – | NA | 0 (0–0) | 0 (0–50) | NA | – | 0 (0–50) | 0.113 |
 Defecation problems (n = 29) | 33.3 (0–85.7) | 23.8 (4.8–42.9) | 33.3 (0–81) | 33.3 (4.8–85.7) | NA | 30.9 (0–57.1) | 33.3 (0–85.7) | 0.425 | 38.1 (4.8–85.7) | 7.1 (0–33.3) | 0.001 | 38.1 (4.8–85.7) | 30.9 (0–81) | 0.502 |
 Weight loss (n = 29) | 0 (0–100) | 0 (0–100) | 0 (0–66.7) | 0 (0–33.3) | N/A | 0 (0–100) | 0 (0–66.7) | 0.621 | 0 (0–100) | 0 (0–0) | 0.097 | 0 (0–33.3) | 0 (0–100) | 1.00 |